Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma

Sorafenib, the only approved drug for hepatocellular carcinoma, acts as a remarkable inhibitor of Raf serine‐threonine kinases. However, Sorafenib is expensive, and clinical experience shows that it is not an effective treatment for many patients. Previous study has demonstrated that phosphorylated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Med
Hauptverfasser: Liang, Yuelong, Chen, Jiang, Yu, Qingsong, Ji, Tong, Zhang, Bin, Xu, Junjie, Dai, Yi, Xie, Yangyang, Lin, Hui, Liang, Xiao, Cai, Xiujun
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Clinical Cancer Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727337/
https://ncbi.nlm.nih.gov/pubmed/29030911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1228
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge